HIV/AIDS Gene Therapy
Modified promoter improves anti-HIV siRNA efficacy
Published in Gene Therapy Weekly, October 30th, 2003
"RNA interference (RNAi) is mediated by small interfering (si) RNAs that target and degrade mRNA in a sequence-specific manner," scientists in Rhode Island explained. "Cellular expression of siRNA can be achieved by the use of expression cassettes driven by RNA polymerase III (pol III) promoters."
In a recent study, D. Boden and colleagues at Brown University found that "a modified tRNA(met)-derived (MTD) promoter effectively drives the cellular expression of HIV-1-specific siRNA."
"We observed up to 56% greater inhibition of virus production when the MTD promoter was used...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2003-10-30)
More Articles from Gene Therapy Weekly
- Drug Resistance
Gene therapy and chemotherapy combine to stop breast cancer and its metastasis - Gynecology
Alternative cell entry allows oncolytic agents to target ovarian cancer - Cardiology
Fusion between recipient- and donor-derived cells is a rare occurrence - Gene Transfer
A new gene delivery method may ameliorate cancer recurrence after resection - Head and Neck Cancer
Adenovirus-mediated p16 gene therapy combats radiation-resistant cancer cells - Pain Medicine
Glial cell-derived neurotrophic factor genes relieve neurotrophic pain - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
